Heng Rui, Enhua to meet the enemy! This Zhejiang pharmaceutical company stirs up anti-epileptic drugs.

Pharmaceutical Network July 27th, July 24, CDE official website shows that Zhejiang Yongtai Pharmaceuticalco's Gaba ding capsule 4 types of imitation listing application was accepted.Minet data show that in 2019 China's public medical institutions terminal Gabardin capsule sales reached 182 million yuan, only The production enterprises Ofchina Pharmaceuticals and Hengrui Pharmaceuticals two.data show that the Gaba-Lamber capsule was developed by Warner-Lamber in the United States and was first approved for listing in the United Kingdom in May 1993, approved by the FDA for listing in the United States in December of the same year, and was acquired by Pfizer in 2000.was approved for listing in Germany in October 2000.october 2010, Gabadin capsules were approved for import into China for the treatment of epilepsy, and the import registration license expired in December 2014.in recent years, China's public medical institutions terminal gabar ding capsule sales (units: 10,000 yuan) minet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal Gabadin capsule sales reached 182 million yuan, production enterprises only Enhua Pharmaceuticals and Hengrui Pharmaceuticals two, of which, Enhua Pharmaceuticals, the largest market share of more than 6percent.consistency evaluation, Enhua Pharmaceuticals and Hengrui Pharmaceuticals were approved to supplement the application, and Hengrui Pharmaceuticals was the first to evaluate the enterprise. Before the, Beijing Shiring Pharmaceuticals and Shandong Longno submitted listing applications in the review and approval (at the Drug Review Center) in the review and approval of four categories.Source: CDE Official Website, Minet.com Database.